Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 5/20 | 0.48 |
| ▸ | MAOA | P21397 | 5/20 | 0.48 |
| ▸ | ACHE | P22303 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282233 | 0.83 | MYC (0.58) | MAPTHPGDKMT2AMEN1HTT | |
| SCHEMBL3284599 | 0.80 | KMT2A (0.51) | HPGDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL3177292 | 0.78 | HDAC1 (0.54) | GPR183PRMT5WDR77 | |
| SCHEMBL3177302 | 0.78 | HDAC1 (0.54) | GPR183PRMT5WDR77 | |
| SCHEMBL29374171 | 0.78 | PRMT5 (0.57) | MAPTHPGDKMT2AMEN1HTT | |
| SCHEMBL12684545 | 0.77 | HDAC6 (0.59) | MAPTHPGDKMT2AMEN1HTT | |
| SCHEMBL28242857 | 0.75 | PRMT5 (0.52) | HPGDKMT2AMEN1NPC1MYC | |
| SCHEMBL3095935 | 0.75 | MAPT (0.54) | MAPTHPGDKMT2AMEN1HTT | |
| SCHEMBL3095929 | 0.75 | MAPT (0.54) | MAPTHPGDKMT2AMEN1HTT | |
| SCHEMBL3287775 | 0.74 | MYC (0.57) | HPGDKMT2AMAPK1LMNAMYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | MAPT 87/4885HPGD 489/4885KMT2A 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.